Immunomic Therapeutics (ITI) is a clinical stage biotechnology company pioneering investigational technologies that have the potential to alter how immunotherapy is used for cancer, allergies, and animal health. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory.
ITI was interested in bringing visibility to its LAMP-Vax technology capabilities, as well as expanding prospects for collaborations and partnerships within this highly dynamic field. But science and health innovation do not exist in a vacuum. There are cultural, social, and political aspects that can have a profound effect on funding priorities, public acceptance of new technologies, and mandates; not to mention the larger questions around individualism versus the greater good. So it was important to build bridges of goodwill and common ground among opinion leaders in science, policy, and business.
To help navigate that tricky landscape, ITI partnered with Scientific American Custom Media to explore the future of vaccine technology in light of some of the most pressing and significant social, political, and cultural challenges. The Scientific American Custom Media team developed the following:
In a series of salon-style events, researchers, policy makers, and business executives convened to explore the critical conversations happening around immunotherapy.
The key discussion points from these events were the driving force behind branded content that was developed for Scientific American, accessible both online and in print.